Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Cardiovascular and Metabolic Risk
Sodium
610
3. Good health
03 medical and health sciences
Glucose
0302 clinical medicine
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Humans
Diabetic Nephropathies
Renal Insufficiency, Chronic
DOI:
10.2337/dc22-0294
Publication Date:
2022-08-16T08:51:58Z
AUTHORS (1342)
ABSTRACT
Finerenone reduced the risk of kidney and cardiovascular events in people with chronic disease (CKD) type 2 diabetes FIDELIO-DKD FIGARO-DKD phase 3 studies. Effects finerenone on outcomes patients taking sodium-glucose cotransporter inhibitors (SGLT2is) were evaluated a prespecified pooled analysis these studies.Patients urine albumin-to-creatinine ratio (UACR) ≥30 to ≤5,000 mg/g estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 randomly assigned or placebo; SGLT2is permitted at any time. Outcomes included composite (cardiovascular death, nonfatal myocardial infarction, stroke, hospitalization for heart failure) (kidney failure, sustained ≥57% eGFR decline, renal death) end points, changes UACR eGFR, safety outcomes.Among 13,026 patients, 877 (6.7%) received an SGLT2i baseline 1,113 (8.5%) initiated one during trial. For composite, hazard ratios (HRs) 0.87 (95% CI 0.79-0.96) without 0.67 0.42-1.07) SGLT2i. HRs 0.80 0.69-0.92) 0.42 0.16-1.08) Baseline use did not affect reduction composites (Pinteraction = 0.46 0.29, respectively); neither concomitant study treatment.Benefits compared placebo cardiorenal CKD observed irrespective use.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (18)
CITATIONS (100)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....